Liquidia Q3 2025: first YUTREPIA sales of $51.7M, achieves profitability, net loss narrows to $3.5M

Liquidia Corp

2025-Q3 EPS reported -$0.97 revenue$66,299,000

Net product sales of YUTREPIA $51.7M in first full quarter post-launch; operating income of $1.7M, positive adjusted EBITDA $10.1M.
Net loss narrowed to $3.5M ($0.04 loss per share) from $31.0M ($0.40 loss per share) in Q3 2024.
More than 2,000 unique patient prescriptions and 1,500 patient starts to date, supported by 600+ prescribers.
Cash and equivalents $157.5M at Sept 30, 2025; R&D down 21% to $9.3M; SG&A up 98% to $40.1M reflecting commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.